MAC Clinical Research and Kariya Pharmaceuticals are pleased to share the successful dosing of the first cohort in the Phase 1 Multiple Ascending Dose (MAD) study for promising new Parkinson’s drug, KP405.
MAC has partnered with Kariya Pharmaceuticals to deliver this single-centre, placebo-controlled study at our Manchester Early Phase Unit. In addition to conducting the clinical delivery at site, MAC is providing full-service support, including project management, clinical monitoring, data management, statistical programming, medical writing, recruitment, regulatory affairs, and study start-up through to close-out.
The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of KP405 in healthy participants and patients with Parkinson’s Disease.
Dr John Connell, Chief Scientific Officer at MAC Clinical Research states “Completing dosing for the first cohort is a great achievement for the team and an important step in understanding the potential of KP405. We’re proud to be working with Kariya on a compound that could represent meaningful progress in the treatment of Parkinson’s Disease.”
MAC has a long and extensive history in CNS and neurodegenerative diseases with 72% of our studies falling within a CNS therapeutic area. We have conducted seven Parkinson’s Disease studies in the past five years. Our vast experience gives us an advantage in ensuring the successful and efficient delivery of this study.
Read the full press release issued by Kariya Pharmaceuticals here.
